Oxford’s PepGen Launches Into DMD With Next-Gen Oligonucleotide Platform
Aims To Challenge Sarepta
Arising from an Oxford and Cambridge university collaboration, the spin-out has selected Duchenne muscular dystrophy as the first target for its peptide platform.
